Smoking cessation counseling in patients with T2DM and TUD (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
5,954	semaglutide	insulins	140 (2.4%)	178 (3.0%)	-0.6% (-1.2%, -0.1%)	0.72 (0.58–0.90)
5,955	semaglutide	metformin	140 (2.4%)	176 (3.0%)	-0.6% (-1.2%, -0.0%)	0.79 (0.63–0.98)
4,831	semaglutide	DPP-4i	109 (2.3%)	154 (3.2%)	-0.9% (-1.6%, -0.3%)) -	0.69 (0.54–0.88)
5,325	semaglutide	SGLT2i	122 (2.3%)	143 (2.7%)	-0.4% (-1.0%, 0.2%)	⊢	0.83 (0.65–1.05)
5,388	semaglutide	SU	127 (2.4%)	153 (2.8%)	-0.5% (-1.1%, 0.1%)	⊢ •	0.81 (0.64–1.02)
2,659	semaglutide	TZD	47 (1.8%)	53 (2.0%)	-0.2% (-1.0%, 0.5%)	⊢	0.85 (0.58–1.26)
5,337	semaglutide	other GLP-1RAs	124 (2.3%)	149 (2.8%)	-0.5% (-1.1%, 0.1%)	⊢	0.82 (0.64–1.04)
						0.30 0.40 0.60 0.801.0	2.0 3.00
						Hazard Ratio (